CVR - Coronavirus Vaccines R&D Roadmap

Milestone
3.5.a

LMIC clinical trials

In progress

Advance the involvement of LMICs in clinical development programs.

Progress Highlights

Mahoney 2023 describes how the Texas Children’s Hospital Center for Vaccine Development has partnered with several LMIC vaccine manufacturers to develop and test coronavirus vaccines.

The International Vaccine Institute (IVI), in collaboration with CEPI, formed a global consortium to develop broadly proactive coronavirus vaccines. IVI and its consortium partners, in alignment with CEPI’s Equitable Access Policy, have committed to equitable vaccine access, with BioNet ensuring affordability and plans for future technology transfer to LMIC producers.

Hamaluba 2023 describes how SARS-CoV-2 vaccine candidate AZD2222 (ChAdOx1 nCoV-19) had clinical trials conducted in several LMICS, although the candidate is no longer active.

SARS-CoV-2 vaccine candidate SkyCovion had clinical trial locations in LMICs (NCT05007951), although the candidate is no longer active.